GF CSI Innovative Drugs Industry ETF (515120) fell 1.87%, with AUM increasing by RMB 2.478 billion over the past three months

newtimespace (newtimespace.com) reported, as of 11:17 on August 14, 2026, GF CSI Innovative Drugs Industry ETF (515120) fell 1.87%, with the latest price at RMB 0.68. Over a longer horizon, as of August 13, 2026, the ETF has gained 8.76% cumulatively over the past week.

In terms of liquidity, the ETF's intraday turnover rate was 4.04%, with turnover of RMB 482 million. Over a longer horizon, as of August 13, the ETF's average daily turnover over the past week was RMB 1.175 billion, placing it among the top 2 comparable funds.

In terms of scale, the ETF's AUM grew by RMB 2.478 billion over the past three months, achieving significant growth; the increase in AUM ranked 2nd out of 7 comparable funds. (Source: Wind)

In terms of shares, the ETF's shares outstanding grew by 1.451 billion units over the past three months, achieving significant growth; the increase in shares ranked 2nd out of 7 comparable funds. (Source: Wind)

Data shows that leveraged funds continue to position. The ETF's margin net buying on the previous trading day reached RMB 19.4430 million, and its latest margin balance reached RMB 387 million. (Source: Wind)

As of August 13, the ETF's NAV has risen 47.09% over the past two years. In terms of return capability, as of August 13, 2026, since its inception, the ETF's highest single-month return was 23.00%, its longest consecutive monthly gain streak was 5 months, its longest consecutive gain was 32.68%, and its average return in rising months was 5.46%. As of August 13, 2026, the ETF's annualized excess return over the benchmark over the past three months was 5.68%.

In terms of drawdown, as of August 13, 2026, the ETF's drawdown relative to its benchmark over the past half year was 0.14%, indicating relatively low drawdown risk among comparable funds. The number of days to recover from the drawdown was 36 days.

In terms of fees, the ETF's management fee rate is 0.50% and its custodian fee rate is 0.10%.

In terms of tracking precision, as of August 13, 2026, the ETF's tracking error over the past five years was 0.026%, the highest tracking precision among comparable funds.

GF CSI Innovative Drugs Industry ETF closely tracks the CSI Innovative Drugs Industry Index. The CSI Innovative Drugs Industry Index selects no more than 50 of the most representative listed companies' securities from those whose main businesses involve innovative drug R&D as its constituents, so as to reflect the overall performance of securities of listed companies in the innovative drugs industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.